FDA Grants Fast Track to DOC1021 for Metastatic and Unresectable Melanoma

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021, an immunotherapy developed by Diakonos Oncology Corp., for the treatment of patients with unresectable or metastatic cutaneous melanoma.

This announcement, made in a news release issued by the Houston-based biotechnology company, aims to expedite the development and review of a patient-derived therapy for individuals whose skin cancer cannot be surgically removed or has spread to distant organs. The designation reflects the urgent need for new treatment options for patients who may not respond to current standards of care.

Main data that support the findings

The FDA's decision to grant Fast Track status is based on the potential of DOC1021 to address a significant unmet medical need in the treatment of advanced melanoma. While targeted therapies and immune checkpoint inhibitors have improved outcomes for some individuals, many patients with cancer continue to experience disease progression or limited durability of response.

DOC1021 is a double-loaded dendritic cell therapy that utilizes a patient’s own immune cells. The treatment is manufactured by combining tumor lysate with amplified tumor-derived mRNA, both of which are prepared from freshly obtained specimens of the patient’s own tumor. This approach is intended to act as a physiologic mimic of a viral infection. By using this double-loading technique, the therapy aims to unlock a synergistic response that is exponentially more powerful than traditional methods.

According to Diakonos Oncology, this mechanism allows for the complete targeting of the total cancer antigen pool. Because it leverages the full complement of tumor antigens, the therapy is designed to drive meaningful anti-tumor immune responses that may be more durable than existing options.

Trial details

Diakonos Oncology is currently advancing DOC1021 through multiple clinical studies to generate robust data and validate its platform. The specific study related to this latest FDA designation is a phase 1/2 trial in patients with refractory melanoma study is supported by the Cancer Prevention and Research Institute of Texas (CPRIT) and is currently recruiting participants.

In addition to the melanoma program, the DOC1021 platform is being evaluated in other aggressive forms of cancer. Active enrolling clinical trials include a phase 1 study in patients with pancreatic cancer and a phase 2 study in patients with glioblastoma.

The FDA has previously granted Fast Track designation to DOC1021 for both the pancreatic cancer and glioblastoma indications. Furthermore, the glioblastoma program received Orphan Drug Designation in January 2024. These ongoing trials are part of the company's focus on expanding treatment options for patients with advanced cancers through their patient-derived immunotherapy platform.

Safety

The design of DOC1021 includes several features intended to improve the patient experience and safety profile compared to some existing immunotherapies. The manufacturing process does not require any genetic engineering or molecular modification of the patient's immune cells.

For patients receiving the treatment, the administration protocol is different from many intensive cellular therapies. DOC1021 does not require preconditioning chemotherapy, which is often used to deplete existing white blood cells before receiving a transplant or certain cell therapies. Additionally, the treatment does not require the administration of high dose IL-2, a cytokine therapy that can often cause severe side effects.

Because of these factors, DOC1021 is designed for outpatient administration. This delivery model is intended to allow for broad access to the therapy via community cancer centers, potentially reducing the burden on patients with cancer and their caregivers by eliminating the need for extended hospital stays or specialized inpatient care. Diakonos Oncology continues to monitor safety and efficacy as the therapy moves through the phase 1/2 trial for refractory melanoma.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

Reference: “Diakonos Oncology Awarded Fast Track Designation by FDA for DOC1021 (dubodencel) in Unresectable or Metastatic Cutaneous Melanoma,” news release.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.